Carol A. Maggio, Ph.D.


Contact Information

Clinical Pharmacology Program
Obesity Research Center
Department of Medicine, Babcock 10
St. Luke's-Roosevelt Hospital Center
1111 Amsterdam Avenue
New York, NY 10025
Phone: (212) 523-4182
Fax: (212) 523-4181
Email: cmaggio@prodigy.net



Education

1979 Ph.D., Biopsychology, Columbia University, New York City
1976 M.A., Experimental Psychology, Columbia University, New York City
1972 B.A., Psychology, Barnard College, New York City

Fellowships

Honors

Honors

Professional Academic Experience

1996- Associate Research Scientist, Institute of Human Nutrition, Columbia University College of Physicians and Surgeons, New York, NY
1983- Staff Research Associate, Department of Medicine, Obesity Research Center and Clinical Pharmacology Program, St. Luke's-Roosevelt Hospital Center, New York, NY
1984 Adjunct Associate Professor, Bionutrition Program, University of Bridgeport, Bridgeport, CT
1980-83 Adjunct Assistant Professor, Department of Biology, Vassar College, Poughkeepsie, NY
1979-82 NIH Postdoctoral Fellow, Columbia University Institute of Human Nutrition (In residence at Vassar College) Sponsor: Dr. M.R.C. Greenwood
1973-79 Graduate Research Assistant, Department of Psychology, Columbia University. Sponsor: Dr. Henry S. Koopmans
1972 Teaching Assistant, Dept. of Psychology, Barnard College

Clinical Research Experience

For over 15 years, I have been involved at St. Luke's-Roosevelt Hospital Center in clinical trials of drugs and treatments for diabetes, obesity, osteoporosis and hyperlipidemia. My responsibilities have included internal quality assurance, protocol implementation, protocol design, preparation of informed consent forms, preparation and publication of results, statistical analysis, case report form maintenance, patient recruitment and selection, training and supervision of study personnel, and frequent contact with pharmaceutical company representatives.

Consulting and Medical Writing

1999-2000 Preparation of symposium proceedings, "Current Developments in the Evaluation and Treatment of Malnutrition". Serono Laboratories, Norwell, MA
1998-2001 Preparation of manuscripts on antiobesity drugs. Ingenix Pharmaceutical Services (Applied Clinical Communications, Inc.), Parsippany, NJ
1998-2003 Preparation of clinical study reports and auditing of case report forms in clinical trials of infertility and prostate cancer drugs. Ferring Pharmaceuticals, Tarrytown, NY
1997-1998 Data management, including auditing of case report forms and data validation in rheumatoid arthritis trials. Markus Research Inc., New City, NY
1996 Writer/editor of educational material and manuscripts on metabolic drugs. Scientific Relations, Bayer Corp., West Haven, CT
1993- Writer/editor of FDA reports and manuscripts. McNeil Nutritionals, New Brunswick, NJ
1992-1995 Data management, including auditing of case report forms and data validation, metabolic disorders and cardiovascular surgery. Medical Affairs, Bayer Corp., Pharmaceutical Division, West Haven, CT
1992 Senior writer/editor of clinical pharmaceutical monographs and meeting reports. Medical Education Programs Limited, Wilton, CT
1992-1993 Editor of meeting proceedings on diabetes drugs. Institute for Preclinical Pharmacology, Miles Inc., Pharmaceutical Division, West Haven, CT
1990-1995 NDA and medical research report preparation, Clinical Pharmacology. Miles Inc., Metabolic/Gastrointestinal Division, West Haven, CT
1988 Consultant in metabolic research. Institute for Preclinical Pharmacology, Miles Inc., West Haven, CT
1983 Report on Hypertension Incidence and Control. WRI, Albany, NY

Basic Research Funding

1988-92 Principal Investigator, NIH RO1 DK25141
Behavioral and Metabolic Correlates of Genetic Obesity
1989-91 Weight Watchers Foundation Inc.
Nutrient Determinants of Satiety in the Obese
1987-88 Miles Institute for Preclinical Pharmacology
Effects of Acarbose (BAY G 5421) on the Onset and Severity of Diabetes in Streptozotocin-injected Rats
1984-87 NIH New Investigator Award R23 AM34342
Macronutrient Influences on Satiety in Obese States
1983-86 Co-Investigator, NIH RO1 AM25141
Behavioral and Metabolic Correlates of Genetic Obesity
1983-84 Obesity CORE Center Feasibility Grant P30 AM26687
Gastrointestinal Satiety Mechanisms in Obese States

Reviewer for the Following Journals

Committees

1998-2000 Chair, Nominating Committee, Society for the Study of Ingestive Behavior
1991-1997 Secretary and Chair, Membership Committee, Society for the Study of Ingestive Behavior
1991-1992 Co-Director, Ingestive Behavior CORE Laboratory, Obesity Research CORE Center
1988-1992 Coordinator, Obesity Research Center Weekly Research Conferences
1986 Organizing Committee, Society for the Study of Ingestive Behavior
1985-1992 Member, St. Luke's-Roosevelt Institute for the Health Sciences Institutional Animal Care and Use Committee

Clinical Trials Experience at St. Luke's-Roosevelt Hospital Center

  1. A Double-Blind, Dose-Ranging, Cross-Over Inpatient Study of the Effect of Naltrexone on Weight Loss in Moderately Obese Men - Du Pont Pharmaceuticals, 1983
  2. A Multi-Center, Double-Blind, Comparative Study of the Long-Term Efficacy and Safety of BAY g 5421 (Acarbose) vs. Placebo in the Treatment of Insulin-Dependent (Type I) Diabetes Mellitus - Miles Inc., 1987
  3. A Multi-Center, Double-Blind, Comparative Study of the Long-Term Efficacy and Safety of BAY m 1099 (Miglitol) vs. Placebo in the Treatment of Non-Insulin-Dependent (Type II) Diabetes Mellitus - Miles Inc., 1988 Clinical Trials, cont'd.
  4. A Multi-Center, Double-Blind, Comparative Study of the Long-Term Safety of Bay g 5421 (Acarbose) vs. Placebo in the Treatment of Insulin-Dependent (Type I) and Non-Insulin-Dependent (Type II) Diabetes Mellitus - Miles Inc., 1991
  5. A Sixteen-Week, Double-Blind, Placebo-Controlled Dose-Response Study Using Glipizide GITS (5, 10, 15, 20 mg) for the Treatment of Non-Insulin-Dependent Diabetes Mellitus - Pfizer Inc., 1991
  6. A Double-Blind, Placebo-Controlled, Crossover Study of the Effects of Sucralose on Serum Glucose and C-Peptide in Patients with Diabetes Mellitus - McNeil Specialty Products Company, 1993
  7. A Phase III Study of Intermittent Cyclical Tiludronate in the Treatment of Established Post-Menopausal Osteoporosis - Sterling Winthrop Pharmaceuticals, 1993
  8. A Multi-Center Pilot Study to Assess the Acceptability of a Prepared Diet in an Adult Population with Generalized Cardiovascular and Metabolic Disease - Campbell Center for Nutrition and Wellness, Campbell Soup Company, 1994
  9. A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study of Oral Zopolrestat in Normotensive, Type I Diabetics with Incipient Nephropathy (Microalbuminuria) - Pfizer, 1994
  10. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Tibolone in Prevention of Osteoporosis in Postmenopausal Women - Organon Inc., 1994
  11. A Multi-Center, Two-Period (Single-Blind Treatment Followed by Randomized, Double-Blind, Placebo-Controlled Withdrawal Periods) Study in Diabetic Patients with Symptoms of Gastroparesis Treated with Domperidone 20 mg before Meals and at Bedtime - Janssen Pharmaceutica, Inc., 1995
  12. A Multicenter Study to Assess a Prepared Diet Program vs. Self-Selected Foods in an Adult Population with Generalized Cardiovascular and Metabolic Disease - Campbell Center for Nutrition and Wellness, Campbell Soup Company, 1995
  13. Double-Blind, Placebo-Controlled, Randomized Multicenter Study on the Efficacy and Safety of Ibandronate (BM 21.0955) during 3 Years Treatment in Patients with Postmenopausal Osteoporosis Using an Intermittent (Every 3 Months) I.V. Injection Regimen of 0.5 and 1.0 mg - Boehringer Mannheim Pharmaceutical Corp., 1996
  14. A Multi-Center, Randomized, Parallel Group, 8-Week Comparative Dose Efficacy and Safety Study of Once-Daily Atorvastatin, Pravastatin, Simvastatin and Fluvastatin in Patients with Elevated LDL-Cholesterol - Parke-Davis, 1996
  15. A Prospective, Double-Blind, Randomized Study of the Safety and Efficacy of Lower Doses of Premarin and Medroxyprogesterone Acetate in Postmenopausal Women (The HOPE Study) -Wyeth-Ayerst, 1996
  16. A Three-Month Study of the Effect of a New Non-Caloric Sweetener on Glucose Homeostasis in Patients with Non-Insulin-Dependent (Type II) Diabetes Mellitus - McNeil Specialty Products Company, 1996
  17. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 24-Week Study of Sibutramine Hydrochloride 20 mg on Weight Loss and Glycemic Control in Obese Patients with Non-Insulin Dependent Diabetes Mellitus Uncontrolled on Diet or Oral Antidiabetic Therapy - Knoll Pharmaceutical Company, 1996
  18. A Study to Evaluate the Safety and Efficacy of Timed Medications in the Treatment of Obese Type II Diabetics Maintained on Diet Therapy - Ergo Science, 1996
  19. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Measuring the Effects of CI-991 With or Without Insulin on Reaching a Treatment Target in Non-Insulin-Dependent Diabetes Mellitus (NIDDM) Patients Requiring Insulin - Parke-Davis, 1996
  20. Effects of Long-Term Prepared Meal Program vs. Usual Therapeutic Diet Instruction on Cardiovascular Risk Factors - Campbell Center for Nutrition and Wellness, Campbell Soup Company, 1997
  21. A Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Sustained Release Dexfenfluramine in Obese Outpatients - Wyeth-Ayerst, 1997
  22. A Study to Evaluate the Safety and Efficacy of Varying Doses of Timed Medications in the Treatment of Obesity - Ergo Science, 1997
  23. A Twenty-Four Week Open-Label Pilot Study to Evaluate the Safety and Efficacy of Adjunctive Meridia (Sibutramine HCl) Treatment in Conjunction with the LEARN Program of Nutrition, Physical Activity, and Lifestyle Modification in Obese Patients - Knoll Pharmaceutical Co., 1998
  24. A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of a Combination of Insulin and Two Doses of Pioglitazone (15 or 30 mg) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) - Takeda America, Inc., 1998
  25. A Double-Blind, Placebo-Controlled Pilot Trial to Determine the Efficacy of Domperidone in Improving Glycemic Control and Upper Gastrointestinal Symptoms in Type 2 Diabetic Patients - Janssen Pharmaceutica, Inc., 1998
  26. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group 18-Month Study to Assess the Safety and Efficacy of MeridiaTM (Sibutramine Hydrochloride) 20 mg When Given in Titrated Doses to Patients with Obesity - Knoll Pharmaceuticals, 1998
  27. A 52-Week, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Orlistat Treatment in Obese Type 2 Diabetic Patients Receiving Insulin - Roche Global Development, 1998
  28. A 26-week, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone (2 mg BID and 4 mg BID) versus Placebo in Combination with Glyburide and Metformin in Patients with Type 2 Diabetes Mellitus - SmithKline Beecham Pharmaceuticals, 1999
  29. A 2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Glipizide Therapy - SmithKline Beecham Pharmaceuticals, 1999
  30. A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Subcutaneously Administered A-300 in Obese Subjects - Amgen, Inc., 1999
  31. Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial - Pfizer Inc., 1999
  32. Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial - Pfizer Inc., 1999
  33. Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus Not Well Controlled with Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial - Pfizer Inc., 1999
  34. A Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Three Doses of SR141716 in Obese Patients - Sanofi-Synthelabo Research, 1999
  35. A Phase III, Multi-Center, Two-Arm Study to Assess the Efficacy and Safety of Ecopipam (SCH39166) in the Management of Obesity - Schering-Plough Research Institute, 2000
  36. A Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Insulin and 45 mg of ACTOSTM (Pioglitazone HCl) Compared to a Combination of Insulin and 30 mg of ACTOSTM (Pioglitazone HCl) in the Treatment of Patients with Type 2 (Non-Insulin Dependent) Diabetes Mellitus - Takeda America Research & Development Center, Inc., 2000
  37. A Phase III, Multicenter, Two-Arm Study to Assess the Efficacy and Safety of Ecopipam (SCH 39166) in the Treatment of Obesity in Subjects with Type 2 Diabetes Mellitus - Schering-Plough Research Institute, 2000
  38. Clinical Effectiveness of the Diasensor 2000Ò Noninvasive Glucose Monitor Used in a Decentralized Clinical Environment - Biocontrol Technology, Inc., 2001
  39. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety of SR141716 in Obese Patients with or without Comorbidities (RIO-North America) - Sanofi-Synthelabo Research, 2001
  40. Long-Term Safety of EXUBERAâ (Inhaled Insulin): Extension of Therapy in Subjects with Type 1 and Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials - Pfizer Inc., 2001
  41. A Multinational, Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, 2 X 2 Factorial Design Study of the Efficacy and Safety of Long-Term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects with Impaired Glucose Tolerance (IGT) - Novartis Pharmaceuticals, 2002
  42. A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multi-Center Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects with Type 2 Diabetes Mellitus Treated with Metformin - Amylin Pharmaceuticals, 2002.
  43. A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multi-Center Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects with Type 2 Diabetes Mellitus Treated with a Sulfonylurea Alone - Amylin Pharmaceuticals, 2002.
  44. A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multi-Center Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects with Type 2 Diabetes Mellitus Treated with Metformin and a Sulfonylurea - Amylin Pharmaceuticals, 2002.
  45. Dose-Finding, Efficacy and Safety Study of AZ242 in Subjects with Type 2 Diabetes - AstraZeneca Pharmaceuticals, 2002.
  46. Glycemic Response to Equi-Sweet Aqueous Solutions of Granular SplendaÒ No Calorie Sweetener or Sucrose Compared to the Glycemic Response to a Standard Glucose Solution: A Randomized, Double-Blind Cross-Over Study in Normal Weight, Normoglycemic Male Volunteers - McNeil Nutritionals, 2003.
  47. Actos Now For Prevention of Diabetes (Act Now) - Takeda Pharmaceuticals, 2003.
  48. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose-Range Finding Study of Once-Daily Dosing of L-000224715 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - Merck & Co., Inc., 2003.
  49. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Topiramate OROSÒ Controlled-Release in the Treatment of Obese, Type 2 Diabetic Subjects Managed with Diet or Metformin - Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 2003.
  50. A Mulitcenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg bid or 100 mg qd) to Placebo in Drug Naïve Patients with Type 2 Diabetes - Novartis Pharmaceuticals, 2004
  51. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy - Novartis Pharmaceuticals, 2004
  52. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Sulfonylurea - Novartis Pharmaceuticals, 2004
  53. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 50 mg bid to Placebo as Add-on Therapy in Patients with Type 2 Diabetes Treated with Insulin - Novartis, 2004
  54. A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - Merck & Co., Inc., 2004
  55. A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - Merck & Co., Inc., 2005
  56. A Randomized, Double-Blind, Two Arms, Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients - Sanofi-Aventis, 2005
Publications
  1. Koopmans, H.S. and C.A. Maggio. The effects of specified chemical meals on food intake. Am. J. Clin. Nutr. 31:267-272, 1978.
  2. Maggio, C.A. The satiety effects of triglycerides with different chain length. Doctoral dissertation, Columbia University, 1979.
  3. Sorette, M.P., C.A. Maggio, A. Starpoli, A. Boissevain and M.R.C. Greenwood. Maternal ethanol intake effects rat organ development despite adequate nutrition. Neurobehav. Toxicol. 2:181-188, 1980.
  4. Maggio, C.A. and H.S. Koopmans. Food intake after intragastric meals of short-, medium-, or long-chain triglyceride. Physiol. Behav. 28:921-926, 1982.
  5. Greenwood, M.R.C., C.A. Maggio, H.S. Koopmans and A. Sclafani. Zucker fafa rats maintain their obese body composition ten months after jejunoileal bypass surgery. Int. J. Obesity 6:513-525, 1982.
  6. Turkenkopf, I.J., C.A. Maggio and M.R.C. Greenwood. Effects of high fat weanling diets containing either medium-chain triglycerides or long-chain triglycerides on the development of obesity in the Zucker rat. J. Nutr. 112:1254-1263, 1982.
  7. Maggio, C.A. and M.R.C. Greenwood. Adipose tissue lipoprotein lipase (LPL) and triglyceride uptake in Zucker rats. Physiol. Behav. 29:1147-1152, 1982.
  8. Maggio, C.A., J.R. Vasselli and M.R.C. Greenwood. The satiety effects of intragastric macronutrient infusions in fatty and lean Zucker rats. Physiol. Behav. 31:367-372, 1983.
  9. Vasselli, J.R., E. Haraczkiewicz, C.A. Maggio and M.R.C. Greenwood. Effects of a glucosidase inhibitor (BAY G 5421) on the development of obesity and food motivated behavior in Zucker (fafa) rats. Pharmacol. Biochem. Behav. 19:85-95, 1983.
  10. Maggio, C.A., M.U. Yang and J.R. Vasselli. Developmental aspects of macronutrient selection in genetically obese and lean rats. Nutr. Behav. 2(2): 93-105, 1984.
  11. Maggio, C.A., E. Presta, E.F. Bracco, H.R. Kissileff, J.R. Vasselli, D.N. Pfohl and S.A. Hashim. Naltrexone and human feeding behavior: a dose-ranging inpatient trial in moderately obese men. Brain Res. Bull. 14:657-661, 1985.
  12. Maggio, C.A., J.R. Vasselli and T.B. Van Itallie. Changes in appetitive behavior following fasting and food restriction. Medicographia 8:10-13, 1986.
  13. Maggio, C.A. and H.S. Koopmans. Satiety effects of intragastric meals containing triglycerides with different chain length. Am. J. Physiol. 252:R1106-R1113, 1987.
  14. Vasselli, J.R. and C.A. Maggio. Mechanisms of appetite and body weight regulation. In: Obesity and Weight Control. The Health Professional's Guide to Understanding and Treatment. R.T. Frankel and M.U. Yang (eds.), pp. 17-34, Aspen Publishers, Rockville, MD, 1987.
  15. Maggio, C.A., L.B. DeCarr and J.R. Vasselli. Differential effects of sugars and the a-glucosidase inhibitor acarbose (BAY G 5421) on satiety in the obese Zucker rat. Int. J. Obesity 11(Suppl.3): 53-56, 1987.
  16. Reed, D., R. Contreas, C.A. Maggio, M.R.C. Greenwood and J. Rodin. Weight cycling in female rats increases dietary fat selection and adiposity. Physiol. Behav. 42:389-395, 1988.
  17. Maggio, C.A., E. Haraczkiewicz and J.R. Vasselli. Diet composition alters the satiety effect of cholecystokinin in lean and obese Zucker rats. Physiol. Behav. 43:485-491, 1988.
  18. Maggio, C.A. and J.R. Vasselli. Satiety in the obese Zucker rat: Effects of carbohydrate type and acarbose (BAY G 5421). Physiol. Behav. 46:557-560, 1989.
  19. Vasselli, J.R. and C.A. Maggio. Diet composition determines course of hyperphagia in developing Zucker fatty rats. Physiol. Behav. 48:805-811, 1990.
  20. Vasselli, J.R., J.A. Fiene and C.A. Maggio. Relationship of adipocyte size to hyperphagia in the developing male obese Zucker rat. Am. J. Physiol. (Regulatory Integrative Comp. Physiol. 31) 262:R33-R38, 1992.
  21. Vasselli, J.R., C.A. Maggio and A. Scriabine (Eds). Drugs In Development, Vol. 1. a-Glucosidase Inhibition: Potential Use in Diabetes, Neva Press, Branford, CT, 1993.
  22. Fried, S.K., C.A. Maggio and J.R. Vasselli. Effects of acarbose on insulin sensitivity in adipocytes of lean and obese Zucker and Zucker diabetic-fatty rats. In: Drugs In Development, Vol. 1. a-Glucosidase Inhibition: Potential Use in Diabetes. J.R.Vasselli, C.A. Maggio, and A. Scriabine, eds., pp.85-93, Neva Press, Branford, CT, 1993.
  23. Maggio, C.A., J.R. Vasselli and F.X. Pi-Sunyer. Acarbose attenuates development of streptozotocin (STZ)-induced diabetes in sucrose-consuming rats. In: Drugs in Development, Vol. 1. a-Glucosidase Inhibition: Potential Use in Diabetes. J.R. Vasselli, C.A. Maggio, and A. Scriabine, eds., pp.85-93, Neva Press, Branford, CT, 1993.
  24. Allison, D.B., F. Paultre, C. Maggio, N. Mezitis and F.X. Pi-Sunyer. The use of areas under curves in diabetes research. Diabetes Care, 18:245-250, 1995.
  25. Mezitis, N.H.E., C.A. Maggio, P. Koch, A. Quddoos, D.B. Allison and F.X. Pi-Sunyer. Glycemic effect of a single high oral dose of the novel sweetener sucralose in patients with diabetes mellitus. Diabetes Care 19:1004-1005, 1996.
  26. Maggio, C.A. and F.X. Pi-Sunyer. The prevention and treatment of obesity: application to type 2 diabetes (Technical Review). Diabetes Care 20: 1744-1766, 1997.
  27. Vasselli, J.R. and C.A. Maggio. Mechanisms of appetite and body weight regulation. In: Overweight and Weight Management. The Health Professional's Guide to Understanding and
  28. Practice. S. Dalton, ed., pp. 187-208, Aspen Press, Gaithersburg, MD, 1997.
  29. Maggio, C.A. and F.X. Pi-Sunyer. The prevention and treatment of obesity: application to type 2 diabetes. Annual Review of Diabetes 195-222, 1998.
  30. Pi-Sunyer, F.X., C.A. Maggio, D.A. McCarron et al. Multicenter randomized trial of a comprehensive meal program in type 2 diabetes. Diabetes Care 22: 191-197, 1999.
  31. Maggio, C.A. and F.X. Pi-Sunyer. Obesity and type 2 diabetes. Endocrinol. Metab. Clin. N. Am. 32: 805-822, 2003.
  32. Maggio, C.A. and F.X. Pi-Sunyer. The prevention and treatment of obesity in Type 2 diabetes: An update (Technical Review) Diabetes Care, in preparation.

Abstracts

  1. Maggio, C.A. and R.S. Canbeyli. Effects of intragastrically delivered sugars with varying structures on food intake. Eastern Psychological Association, New York, 1975.
  2. Maggio, C.A. An assay designed to distinguish discomfort from satiety as a cause of reduced feeding behavior. Eastern Psychological Association, New York, 1976.
  3. Maggio, C.A. The effects of triglycerides of different chain length upon food intake in rats. Eastern Psychological Association, Boston, 1977.
  4. Maggio, C.A. The satiety effects of triglycerides with different chain length. Eastern Psychological Association, Hartford, 1980.
  5. Maggio, C.A. The satiety effects of triglycerides with different chain length. Alim. Nutr. Metab. 1:312, 1980.
  6. Sorette, M.P., C.A. Maggio, A. Starpoli, A. Boissevain and M.R.C. Greenwood. Effect of moderate and high maternal alcohol intake on fetal development. Fed. Proc. 39:846, 1980.
  7. Turkenkopf, I., C.A. Maggio, K. Jensen and M.R.C. Greenwood. High fat diets containing medium-chain triglycerides lower lipoprotein lipase activity and reduce obesity in young Zucker (fafa) rats. Alim. Nutr. Metab. 1:370, 1980.
  8. Greenwood, M.R.C., C.A. Maggio, H.S. Koopmans and A. Sclafani. Zucker (fa/fa) rats maintain obese body composition ten months after intestinal bypass. Fed. Proc. 40(3): 888, 1981.
  9. Turkenkopf, I., C.A. Maggio and M.R.C. Greenwood. Medium chain triglycerides reduce weight but not obesity in young (fa/fa) rats. Fed. Proc. 40(3): 841, 1981.
  10. Maggio, C.A. and M.R.C. Greenwood. Enhanced clearance and adipose tissue storage of intravenous 14C-intralipid in Zucker fatty and lean rats. Fed. Proc. 41(3): 459, 1982.
  11. Maggio, C.A., J.R. Vasselli and M.R.C. Greenwood. The satiating effectiveness of intragastric macronutrient loads in fatty and lean Zucker rats. Eastern Psychological Association, Baltimore, 1982.
  12. Tulp, O.L., M.H. Gregory, C.A. Maggio, M.R.C. Greenwood and O.E. Michaelis. Effect of diet and genotype on growth and adipose cellularity in the corpulent (CORP) rat. Fed. Proc. 41(3) 458, 1982.
  13. Maggio, C.A., M.R.C. Greenwood and J.R. Vasselli. Dietary self-selection and development of obesity in Zucker (fa/fa) rats. Am. J. Clin. Nutr. 35:XXX, 1982.
  14. Maggio, C.A., M.R.C. Greenwood and J.R. Vasselli. The effect of lifelong macronutrient selection on food intake and development of obesity in the Zucker rat. Eastern Psychological Abstracts, Association, 1983.
  15. Maggio, C.A., M.R.C. Greenwood and J.R. Vasselli. Behavioral and metabolic aspects of lifelong macronutrient selection in Zucker obese (fa/fa) rats. IV International Congress on Obesity, 1983.
  16. Vasselli, J.R., M.R.C. Greenwood and C.A. Maggio. Dietary macronutrient content influences developmental hyperphagia but not final body weight in Zucker fatty (fa/fa) rats. IV International Congress on Obesity, 1983.
  17. Vasselli, J.R., C.A. Maggio and E. Haraczkiewicz. Determinants of hyperphagia in Zucker fatty rats. Eastern Psychological Association, 1984.
  18. Maggio, C.A. and J.R. Vasselli. Lifelong macronutrient selection influences food intake and development of obesity in the Zucker (fa/fa) rat. Symposium on "Nutritional Factors in the Control of Food Intake and Body Weight". Western Psychological Association, 1984.
  19. Maggio, C.A., E. Presta, E.F. Bracco, H.R. Kissileff, J.R. Vasselli and S.A. Hashim. Effects of naltrexone on spontaneous food intake of obese men. American Psychological Association, 1984.
  20. Vasselli, J.R., E. Haraczkiewicz and C.A. Maggio. Effect of dietary macronutrient content on hyperphagia and body weight in developing Zucker fatty rats. Satellite Symposium on "The Neural and Metabolic Bases of Feeding." Neuroscience Society Meeting, 1984.
  21. Maggio, C.A., E. Presta, E.F. Bracco, J.R. Vasselli, H.R. Kissileff and S.A. Hashim. Naltrexone and human feeding behavior: A dose-ranging inpatient trial in moderately obese men. Satellite Symposium on "The Neural and Metabolic Bases of Feeding." Neuroscience Society Meeting, 1984.
  22. Maggio, C.A., E. Haraczkiewicz and J.R. Vasselli. Alterations of refeeding following fasting in genetically obese Zucker rats. Int. J. Obesity 9:A105, 1985.
  23. Maggio, C.A., E. Haraczkiewicz and J.R. Vasselli. Diet influences the satiety effect of cholecystokinin (CCK) in Zucker rats. IX International Conference on the Physiology of Food and Fluid Intake, Seattle, 1986.
  24. Haraczkiewicz, E., C.A. Maggio and J.R. Vasselli. Effects of fasting upon refeeding in obese and lean Zucker rats. Proc. Eastern Psychol. Assn. 57:25, 1986.
  25. Maggio, C.A., L.B. DeCarr and J.R. Vasselli. Satiety in the Zucker obese rat: Effects of sugars and acarbose (BAY G 5421). Drugs Regulating Food Intake and Energy Balance. Satellite Symposium of Vth International Congress on Obesity. Rome, 1986.
  26. Maggio, C.A., E. Haraczkiewicz and J.R. Vasselli. Diet influences the satiety effect of cholecystokinin (CCK) in Zucker rats. Fed. Proc. 46:1339, 1987. Maggio, C.A., J. Feine, E. Haraczkiewicz and J.R. Vasselli. Adipose tissue correlates of developmental hyperphagia in Zucker (fa/fa) rats. FASEB J. 2(5): A1198, 1988.
  27. Maggio, C.A. and J.R. Vasselli. Satiety in the Zucker rat: Effects of type of carbohydrate and acarbose. Int. J. Obesity 13:400, 1989.
  28. Maggio, C.A. and J.R. Vasselli. Pharmacological reduction of insulin release decreases hyperphagia and body weight gain in growing obese Zucker rats. Appetite 12:223, 1989.
  29. Vasselli, J.R. and C.A. Maggio. Relationship of adipocyte filling to feeding behavior: Measurements in the hyperphagic Zucker fatty rat. Appetite 12:242, 1989.
  30. Maggio, C.A. and J.R. Vasselli. Effects of long-term pharmacological reduction of insulin release on the development of hyperphagia and obesity in Zucker rats. Int. J. Obesity 13:563, 1989.
  31. Maggio, C.A., F.X. Pi-Sunyer and J.R. Vasselli. Acarbose treatment attenuates development of streptozotocin-induced diabetes. Lessons from Animal Diabetes, Third International Workshop, Jerusalem, Israel, March 1990.
  32. Maggio, C.A. and J.R. Vasselli. Insulin hypersecretion contributes to hyperphagia and obesity in the Zucker rat. FASEB J. 4(3): A511, 1990.
  33. Yang, M.U., C.A. Maggio, H.R. Kissileff and T.B. Van Itallie. Effect of growth hormone on body composition and urinary nitrogen excretion during severe caloric restriction in rats. Int. J. Obesity 14 (Suppl. 2): 116, 1990.
  34. Maggio, C.A. and J.R. Vasselli. Diazoxide inhibition of insulin secretion attenuates obesity in Zucker rats. Pharmacological Treatment of Obesity, Satellite Symposium to 6th International Congress on Obesity, Yokohama, Japan, 1990.
  35. Fried, S.K., D. Buyer, C.A. Maggio and J.R. Vasselli. Glucose metabolism in adipocytes of adult obese Zucker rats: A reappraisal. FASEB J. 5(5): A955, 1991.
  36. Vasselli, J.R. and C.A. Maggio. Duration of developmental hyperphagia in the Zucker fatty rat coincides with adipocyte filling. Int. J. Obesity 15(Suppl.3): 32, 1991.
  37. Maggio, C.A., F.X. Pi-Sunyer and J.R. Vasselli. Acarbose treatment attenuates development of streptozotocin (STZ)-induced diabetes. Miles Institute Preclinical Workshop on Acarbose, Annapolis, MD, October 1991.
  38. Fried, S.K., C.A. Maggio and J.R. Vasselli. Effects of acarbose on adipocyte insulin sensitivity in obese and diabetic rat models. Miles Institute Preclinical Workshop on Acarbose, Annapolis, MD, October 1991.
  39. Maggio, C.A. and J.R. Vasselli. Expression of hyperphagia breakpoint in female obese Zucker rats. Appetite 19(2): 200, 1992.
  40. Mezitis, N., P. Koch, C. Maggio, A. Quddoos and F.X. Pi-Sunyer. Glycemic response to sucralose, a novel sweetener, in subjects with diabetes mellitus. Diabetes 43:261A, 1994.
  41. Vasselli, J.R., K. Chu and C.A. Maggio. Differential responsiveness of Zucker obese (fa/fa), lean (Fa/Fa) and Sprague-Dawley rats to subcutaneous injections of murine leptin (rMuLep). FASEB J. 11(3): A357, 1997.
  42. Vasselli, J.R., K. Chu and C.A. Maggio. Differential effects of subcutaneous injections of rMuLeptin on feeding and body weight in genetically obese, lean and Sprague-Dawley rats. Appetite 29(3): 418, 1997.
  43. Vasselli, J.R., K. Chu, H.R. Kissileff and C.A. Maggio. Resistance to the feeding and body weight-inhibitory effects of peripherally-injected leptin (rMuLep) in Zucker obese and lean rats. Society for Neuroscience Abstracts 24(1): 449, 1998.
  44. Vasselli, J.R., C.P. Koczka, K.A. Singh, C.N. Boozer and C.A. Maggio. Expression of leptin resistance: role of diet vs. increased adiposity. Obesity Research 8(S1): 14S, 2000.

STAFF PAGE
OBESITY RESEARCH CENTER HOME PAGE